Therapeutic efficacy of a MMAE-based anti-DR5 drug conjugate Oba01 in preclinical models of pancreatic cancer

Pancreatic cancer (PC) is among the most aggressive malignancies associated with a 5-year survival rate of <9%, and the treatment options remain limited. Antibody–drug conjugates (ADCs) are a new class of anticancer agents with superior efficacy and safety profiles. We studied the antitumor activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Chao, Zhou, Dongdong, Li, Weisong, Duan, Yanhui, Xu, Minwen, Liu, Jie, Cheng, Jingpei, Xiao, Youban, Xiao, Han, Gan, Tao, Liang, Jianmin, Zheng, Dexian, Wang, Liefeng, Zhang, Shuyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148860/
https://www.ncbi.nlm.nih.gov/pubmed/37120688
http://dx.doi.org/10.1038/s41419-023-05820-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148860/
https://www.ncbi.nlm.nih.gov/pubmed/37120688
http://dx.doi.org/10.1038/s41419-023-05820-1

Ejemplares similares